- Home
- RCG vs APRE Comparison
RCG vs APRE Comparison
Compare RCG & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCG
- APRE
- Stock Information
- Founded
- RCG 1994
- APRE 2006
- Country
- RCG United States
- APRE United States
- Employees
- RCG N/A
- APRE N/A
- Industry
- RCG Investment Managers
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RCG Finance
- APRE Health Care
- Exchange
- RCG Nasdaq
- APRE Nasdaq
- Market Cap
- RCG 15.6M
- APRE 15.8M
- IPO Year
- RCG N/A
- APRE 2019
- Fundamental
- Price
- RCG $2.87
- APRE $4.10
- Analyst Decision
- RCG
- APRE Strong Buy
- Analyst Count
- RCG 0
- APRE 2
- Target Price
- RCG N/A
- APRE $15.50
- AVG Volume (30 Days)
- RCG 5.9K
- APRE 33.0K
- Earning Date
- RCG 01-01-0001
- APRE 11-07-2024
- Dividend Yield
- RCG 0.98%
- APRE N/A
- EPS Growth
- RCG N/A
- APRE N/A
- EPS
- RCG N/A
- APRE N/A
- Revenue
- RCG N/A
- APRE $1,310,839.00
- Revenue This Year
- RCG N/A
- APRE $134.21
- Revenue Next Year
- RCG N/A
- APRE N/A
- P/E Ratio
- RCG N/A
- APRE N/A
- Revenue Growth
- RCG N/A
- APRE 130.31
- 52 Week Low
- RCG $1.52
- APRE $2.15
- 52 Week High
- RCG $1.90
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- RCG 65.66
- APRE 62.50
- Support Level
- RCG $2.32
- APRE $3.34
- Resistance Level
- RCG $2.58
- APRE $4.41
- Average True Range (ATR)
- RCG 0.12
- APRE 0.43
- MACD
- RCG 0.04
- APRE 0.04
- Stochastic Oscillator
- RCG 100.00
- APRE 54.19
About RCG RENN Fund Inc
RENN Fund Inc is active in the financial services domain. It is a closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, Oil and Gas, medical chemicals, botanical products, and others.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.